Clinical epidemiology of extrahepatic manifestations of chronic hepatitis C virus infection

Extrahepatic manifestations occur in more than half of patients with chronic hepatitis C virus infection and may be no less dangerous to the health and life of the patient than the isolated pathology of the liver. Chronic hepatitis C virus infection is often accompanied by the formation of neurocognitive disorders, clinically manifested by general weakness, fatigue and the inability to maindoi tain concentration for a long time. Every fifth patient with chronic hepatitis C develops depression. The development of type 2 diabetes among patients with chronic hepatitis C virus infection is observed 1.7 times more often than among non-infected individuals. Mixed cryoglobulinemia is observed in at least 30% of patients, however, the clinical manifestations of this pathology develop only in 4.9% of cases, of which 69–89% of skin lesions, 19–44% of distal sensory and sensorimotor polyneuropathy, 30% of membranoproliferative glomerulonephritis, 28% of joint damage. Among patients with chronic hepatitis C virus infection, higher prevalence than among non-infected individuals is observed, the prevalence rates of such nosologies as lymphoma from cells of the marginal zone are 2.47 times, diffuse large cell B cell lymphoma – 2.24 times, hypothyroidism – 3.1 time. Significantly more rarely encountered extrahepatic manifestations of chronic hepatitis C virus infection are skin lesions that are not associated with the development of cryoglobulinemic vasculitis: acquired late skin porphyria, necrolytic acral erythema and lichen planus. The question of the pathogenetic relationship of chronic hepatitis C virus infection with cardiovascular pathology remains open.

1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. doi: 10.1016/S0140-6736(14)61682-2.

2. Lee M.H., Yang H.I., Lu S.N., Jen C.L., You S.L., Wang L.Y., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J. Infect.Dis. 2012;206(4):469–477. doi: 10.1093/infdis/jis385.

3. Younossi Z., Park H., Henry L., Adeyemi A., Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599–1608. doi: 10.1053/j.gastro.2016.02.039.

4. Monaco S., Mariotto S., Ferrari S., Calabrese M., Zanusso G., Gajofatto A., et al. Hepatitis C virusassociated neurocognitive and neuropsychiatric disorders: Advances in 2015. World Journal of Gastroenterology. 2015;21(42):11974–11983. doi: 10.3748/wjg.v21.i42.11974.

5. Byrnes V., Miller A., Lowry D., Hill E., Weinstein C., Alsop D., et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. Journal of Hepatology. 2012;56(3):549–556. doi: 10.1016/j.jhep.2011.09.015.

6. Morgello S., Murray J., Van Der Elst S., Byrd D. HCV, but not HIV, is a risk factor for cerebral small vessel disease. Neurology: Neuroimmuno logy&Neuroinflammation. 2014;1(3):e27. doi: 10.1212/NXI.0000000000000027.

7. Enger C., Forssen U.M., Bennett D., Theodore D., Shantakumar S., McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Advances in Therapy. 2014;31(8):891–903. doi: 10.1007/s12325-014-0138-4.

8. Liao C.C., Su T.C., Sung F.C., Chou W.H., Chen T.L. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS ONE. 2012;7(2):e31527. doi: 10.1371/journal.pone.0031527.

9. Huang H., Kang R., Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS ONE. 2013;8(11):e81305. doi: 10.1371/journal.pone.0081305.

10. Wong R.J., Gish R.G. Metabolic manifestations and complications associated with chronic hepatitis C virus infection. Gastroenterology and Hepatology. 2016;12(5):293–299. Available at: https://www.gastroenterologyandhepatology.net/archives/may-2016/metabolic-manifestations-and-complications-associated-withchronic-hepatitis-c-virus-infection/

11. Naing C., Mak J.W., Ahmed S.I., Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World Journal of Gastroenterology. 2012;18(14):1642–1651. doi: 10.3748/wjg.v18.i14.1642.

12. Chandra P.K., Hazari S., Poat B., Gunduz F., Prabhu R., Liu G., et al. Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virol. J. 2010;7:118. doi: 10.1186/1743-422X-7-118.

13. Ostojic P., Jeremic I.R. Managing refractory cryoglobulinemic vasculitis: challenges and solutions. Journal of Inflammation Research. 2017;10:49–54. doi: 10.2147/JIR.S114067.

14. Cacoub P., Comarmond C., Domont F., Savey L., Desbois A.C., Saadoun D. Extrahepatic manifestation of chronic hepatitis C virus infection. Therapeutic Advances in Infectious Disease. 2016;3(1):3–14. doi: 10.1177/2049936115585942.

15. Стельмах В.В., Козлов В.К., Суханов Д.С., Скипский И.М. Васкулит легких как клиниче- ская «маска» HCV-инфекции: эффективность безинтерфероновой противовирусной тера- пии. Терапевтический архив. 2014;11:87–92. Режим доступа: https://www.mediasphera.ru/issues/terapevticheskij-arkh

16. iv/2014/11/030040-366020141117. Stel’mah V.V., Kozlov V.K., Sukhanov D.S., Skipskij I.M. Pulmonary vasculitis as a clinical mask of HCV infection: Efficiency of interferon-free antiviral therapy. Therapeutic archive = Terapevticheskiy arkhiv. 2014;11:87–92. (In Russ.) Available at: https://www.mediasphera.ru/issues/terapevticheskij-arkhiv/2014/11/030040-366020141117.

17. Retamozo S., Díaz-Lagares C., Bosch X., Bové A., Brito-Zerón P., Gómez M.E., et al. Life- threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine. 2013;92(5):273–284. doi: 10.1097/MD.0b013e3182a5cf71.

18. Terrier B., Cacoub P. Renal involvement in HCV-related vasculitis. Clin. Res. Hepatol. Gastroenterol. 2013;37(4):334–339. doi: 10.1016/j.clinre.2013.02.002

19. Tang L., Marcell L., Kottilil S. Systemic manifestations of hepatitis C infection. Infectious Agents and Cancer. 2016;11:29. doi: 10.1186/s13027-016-0076-7.

20. Perico N., Cattaneo D., Bikbov B., Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin. J. Amer. Soc. Nephrol. 2009;4(1):207–220. doi: 10.2215/CJN.03710708.

21. Fabrizi F., Verdesca S., Messa P., Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: A systematic review and meta-analysis. Digestive Diseases and Sciences. 2015;60(12):3801–3813. doi: 10.1007/s10620-015-3801-y.

22. Fabrizi F., Dixit V., Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19(9):601–607. doi: 10.1111/j.1365-2893.2012.01633.x.

23. Shen Y., Wang X.L., Xie J.P., Shao J.G., Lu Y.H., Zhang S., Qin G. Thyroid disturbance in patients with chronic hepatitis C infection: a systematic review and meta-analysis. Journal of gastrointestinal and liver diseases. 2016;25(2):227–234. doi: 10.15403/jgld.2014.1121.252.chc.

24. Blackard J.T., Kong L., Huber A.K., Tomer Y. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of HCV and thyroiditis analysis. Thyroid. 2013;23(7):863–870. doi: 10.1089/thy.2012.0507.

25. Raphael B.A., Dorey-Stein Z.L, Lott J., Amorosa V., Lo Re V 3rd, Kovarik C. Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. J Am Acad Dermatol. 2012;67(5):962–968. doi: 10.1016/j.jaad.2011.11.963.

26. Moneib H.A.M., Salem S.A.M., Darwish M.M. Evaluation of zinc level in skin of patients with necrolytic acral erythema. Br J Dermatol. 2010;163(3):476–480. doi: 10.1111/j.1365-2133.2010.09820.x.

27. Raslan H.M., Ezzat W.M., Abd El Hamid M.F., Emam H., Amre K.S. Skin manifestationsof chronic hepatitis C virus infection in Cairo, Egypt. East Mediterr Health J. 2009;15(3):692–700. Available at: http://www.emro.who.int/emhj-volume-15-2009/volume-15-issue-3/skin-manifestations-of-chronic-hepatitis-cvirus-infection-in-cairo-egypt.html.

28. Petti S., Rabiei M., De Luca M., Scully C. The magnitude of the association between hepatitis C virus infection and oral lichen planus: meta-analysis and case control study. Odontology. 2011;99(2):168–178. doi: 10.1007/s10266-011-0008-3.

29. Pothineni N.V., Delongchamp R., Vallurupalli S., Ding Z., Dai Y., Hagedorn C.H., Mehta J.L. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. American Journal of Cardiology. 2014;114(12):1841–1845. doi: 10.1016/j.amjcard.2014.09.020.

30. Gill K., Ghazinian H., Manch R., Gish R. Hepatitis C virus as a systemic disease: Reaching beyond the liver. Hepatology International. 2016;10(3):415–423. doi: 10.1007/s12072-015-9684-3.

31. Hsu Y.C., Ho H.J., Huang Y.T., Wang H.H., Wu M.S., Lin J.T., Wu C.Y. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495–503. doi: 10.1136/gutjnl-2014-308163.

32. Domont F., Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver International. 2016;36(5):621–627. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26763484.

33. Huang H., Kang R., Zhao Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. PLoS ONE. 2014;9(9):e106376. doi: 10.1371/journal.pone.0106376.

34. Adinolfi L.E., Zampino R., Restivo L., Lonardo A., Guerrera B., Marrone A., et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World Journal of Gastroenterology. 2014;20(13):3410–3417. doi: 10.3748/wjg.v20.i13.3410.

35. Boddi M., Abbate R., Chellini B., Giusti B., Giannini C., Pratesi G., et al. Hepatitis C virus RNA localization in human carotid plaques. Journal of Clinical Virology. 2010;47(1):72–75. doi: 10.1016/j.jcv.2009.10.005